Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Post by MetzGERon Jan 12, 2021 12:05pm
122 Views
Post# 32276340

Hair Regeneration Potential of Human Dermal Sheath Cells

Hair Regeneration Potential of Human Dermal Sheath Cells Very nice article which confirms the efficacy of the Dermal sheath Cup Cells in inducing hair growth:
https://www.liebertpub.com/doi/full/10.1089/ten.tea.2019.0329

i am sure Shiseido Knows how to optimize RCH-01. they Are doing in the actual clinical human Trials lower doses and multiple Injektions.

if you Look at Replicel Animal studies the best results has been archieved were at lower Cell concentrations. 
Shiseido is very Optimistic that is Why they published their Phase II study in media in March 2020.

the actual study will give mich better results and will lead to a huge commercializtion product. Replicel Will Be in all media and the Stock Price Will Go to the moon 
<< Previous
Bullboard Posts
Next >>